Research

UVM faculty members Andrea Villanti, Ph.D., M.P.H., associate professor of psychiatry, and William Copeland, Ph.D., professor of psychiatry, have been named to a list of the world’s most influential researchers - the Highly Cited Researchers list is compiled and published annually by Clarivate Analytics.

University of Vermont Professor of Medicine Daniel Weiss, M.D., Ph.D., has been selected to receive one of the inaugural American Lung Association COVID-19 Action Initiative's COVID-19 and Respiratory Virus Research Award.

The Larner College of Medicine hosted the fifth annual "Dean's Celebration of Excellence in Research" on November 4 and 5. The two-day event highlighted the research being conducted by junior faculty, senior faculty, postdoctoral trainees, and graduate students at the College.

A JAMA Network Open study, led by Stephen T. Higgins, Ph.D., director of the Vermont Center on Behavior and Health at the University of Vermont’s Larner College of Medicine, provides evidence that, even in smokers from vulnerable populations, reducing nicotine content to low levels decreases addictiveness – a timely finding as the Food and Drug Administration (FDA) considers a policy to lower nicotine content in all cigarettes sold in the U.S.

Organized by Black physicians and scientists in the United States and abroad, the #BlackInCardio movement celebrates Black researchers, clinicians, and professionals in cardiovascular fields and raises awareness of cardiovascular diseases that disproportionately effect the Black community. From October 19 - October 25, the new organization will host its first annual #BlackInCardio week.

New research, published in Clinical and Translational Immunology by UVM Associate Professor Sean Diehl, Ph.D., and colleagues provides a clearer picture of the protective antibodies induced by the SARS-C0V-2 virus and their role in serious illness and what’s needed for full protection.

New research, published by scientists at the University of Vermont and Caltech in the journal Cell, has pinpointed three specific mechanisms that allow SARS-CoV-2 to incapacitate human cells by disabling the cell’s alarm system to call for help or warn nearby cells of infection.

Internationally recognized cerebral blood flow expert and University of Vermont Distinguished Professor and Chair of Pharmacology Mark Nelson, Ph.D., delivered a National Institutes of Health (NIH) Director’s Wednesday Afternoon Lecture, titled “Translating Thought into Blood Flow in the Brain: Capillaries as Sensors of Neural Activity,” on October 14.

A team of scientists at the University of Vermont, working in partnership with a group at the University of Washington, has developed a method of testing for the COVID-19 virus that doesn’t make use of these chemicals but still delivers an accurate result, paving the way for inexpensive, widely available testing in both developing countries and industrialized nations like the United States, where reagent supplies are again in short supply.

(OCTOBER 2, 2020) Senior Associate Dean for Research Gordon Jensen, M.D., Ph.D., discussed the $5.4 million National Institutes of Health grant he received to support the creation of the UVM Center for Biomedical Shared Resources on WCAX-TV.